BSH 2023 | Updated analysis of the MAIA trial: long-term safety and efficacy data
Supratik Basu, MBBS, MRCP, FRCPath, FRCP, The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, UK, shares an update on the Phase III MAIA trial (NCT02252172), which is evaluating the safety and efficacy of adding daratumumab to lenalidomide and dexamethasone in patients with transplant-ineligible multiple myeloma. Long-term follow-up data demonstrate that there is a significant progression-free survival and overall survival (PFS; OS) advantage in patients receiving the daratumumab-containing regimen, confirming the well established role of this agent in the upfront and relapsed settings. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
